Next Article in Journal
The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection
Next Article in Special Issue
The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group
Previous Article in Journal
Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis
Previous Article in Special Issue
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens
Review

New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams

Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC-CICA), Complejo Hospitalario Universitario A Coruña (CHUAC), As Xubias 84, 15006 A Coruña, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(23), 9308; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239308
Received: 17 November 2020 / Revised: 27 November 2020 / Accepted: 30 November 2020 / Published: 6 December 2020
Carbapenem resistance is a major global health problem that seriously compromises the treatment of infections caused by nosocomial pathogens. Resistance to carbapenems mainly occurs via the production of carbapenemases, such as VIM, IMP, NDM, KPC and OXA, among others. Preclinical and clinical trials are currently underway to test a new generation of promising inhibitors, together with the recently approved avibactam, relebactam and vaborbactam. This review summarizes the main, most promising carbapenemase inhibitors synthesized to date, as well as their spectrum of activity and current stage of development. We particularly focus on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens of critical priority. The emergence of these new combinations represents a step forward in the fight against antimicrobial resistance, especially in regard to metallo-β-lactamases and carbapenem-hydrolysing class D β-lactamases, not currently inhibited by any clinically approved inhibitor. View Full-Text
Keywords: carbapenemase; inhibitor; antibiotic resistance; carbapenem resistance; metallo-β-lactamases; serine-β-lactamases carbapenemase; inhibitor; antibiotic resistance; carbapenem resistance; metallo-β-lactamases; serine-β-lactamases
Show Figures

Graphical abstract

MDPI and ACS Style

Vázquez-Ucha, J.C.; Arca-Suárez, J.; Bou, G.; Beceiro, A. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams. Int. J. Mol. Sci. 2020, 21, 9308. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239308

AMA Style

Vázquez-Ucha JC, Arca-Suárez J, Bou G, Beceiro A. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams. International Journal of Molecular Sciences. 2020; 21(23):9308. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239308

Chicago/Turabian Style

Vázquez-Ucha, Juan C., Jorge Arca-Suárez, Germán Bou, and Alejandro Beceiro. 2020. "New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams" International Journal of Molecular Sciences 21, no. 23: 9308. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239308

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop